Adverse reactions mediated by Strontium-89, Samarium-153, Rhenium-186 and Rhenium-188: A Systematic Review of Literature

• Autor(a) principal: Pinho, Cláudia
• Data de Publicação: 2023
• Outros Autores: Martins, Sara, Jesus, Ângelo, Suárez, Ana Martín
• Idioma: eng
• Título da fonte: Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
• Texto Completo: http://hdl.handle.net/10400.22/25337
• topic: Pharmacovigilance; Adverse reactions; Radiopharmaceuticals; Bone metastases; Pain palliation

One of the therapies used for the palliative treatment of pain associated with bone metastases is radiopharmaceutical therapy. Radiopharmaceuticals can cause adverse reactions, and, therefore, the aim is to systematize the results and conclusions of studies on the use of the radiopharmaceuticals 89Sr, 153Sm, 186Re and 188Re in the palliative treatment of pain associated with bone metastases. A systematic literature review was conducted according to PRISMA statement, using the databases MEDLINE and EBSCO. After the selection process, 20 articles were included. The studies showed that the 4 radiopharmaceuticals analysed presented very similar results regarding pain relief after treatment, decrease in analgesic consumption, side effects at the time of administration, hematologic toxicity and disease progression after treatment. Concluding, the use of radiopharmaceuticals for pain palliation seems to be safe and an alternative to existing treatments.